World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Best Female Scientists

D-Index
126
Citations
87730
World Ranking
409
National Ranking
18

Medicine

D-Index
135
Citations
100584
World Ranking
2018
National Ranking
98

Sibylle Loibl publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Sibylle Loibl sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,380 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Sibylle Loibl D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Sibylle Loibl sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 135 D-Index — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Germany Leader Award
  • 2025 - Research.com Best Female Scientists Award

Overview

Sibylle Loibl is affiliated with Goethe University Frankfurt in Germany. Their research primarily spans the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a substantial focus on Oncology and Cancer Research. Additional areas of sub-specialization include Pulmonary and Respiratory Medicine, Genetics, and Molecular Biology.

The scientist's work covers several major topics related to cancer, including:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Breast Lesions and Carcinomas
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers

Sibylle Loibl has contributed extensively to the academic literature, with recent notable papers including:

  • "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial" (2020, The Lancet)
  • "Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer" (2021, New England Journal of Medicine)
  • "Breast cancer" (2021, The Lancet)
  • "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer" (2021, New England Journal of Medicine)
  • "ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer" (2021, Annals of Oncology)

The scientist's research has frequently been published in several high-profile journals, including:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • European Journal of Cancer

Collaboration has been a significant aspect of Sibylle Loibl's work, with frequent co-authors including:

  • Carsten Denkert
  • Michael Untch
  • Peter A. Fasching
  • Valentina Nekljudova
  • Andreas Schneeweiß

The breadth of publications and co-authorships indicates active engagement in multi-disciplinary cancer research, placing particular emphasis on breast cancer therapies, molecular and genetic mechanisms of cancer, and clinical applications in oncology.

Best Publications

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

    R. Salgado;C. Denkert;S. Demaria;N. Sirtaine

  • Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl

  • Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Fabrice André;Eva Ciruelos;Gabor Rubovszky;Mario Campone

  • Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

    Carsten Denkert;Sibylle Loibl;Aurelia Noske;Marc Roller

  • Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

    Carsten Denkert;Gunter von Minckwitz;Silvia Darb-Esfahani;Bianca Lederer

  • Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi

  • Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

    S. Loi;S. Loi;S. Michiels;S. Michiels;R. Salgado;N. Sirtaine

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Association analysis identifies 65 new breast cancer risk loci

    Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley

  • Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

    Carsten Denkert;Gunter von Minckwitz;Jan C. Brase;Bruno V. Sinn

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

    Andrew N.J. Tutt;Judy E. Garber;Bella Kaufman;Giuseppe Viale

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

    Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata

  • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

    Gunter von Minckwitz;Andreas Schneeweiss;Sibylle Loibl;Christoph Salat

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

    Nasim Mavaddat;Kyriaki Michailidou;Kyriaki Michailidou;Joe Dennis;Michael Lush

  • HER2-positive breast cancer

    Sibylle Loibl;Luca Gianni

Frequent Co-Authors

Gunter von Minckwitz
Gunter von Minckwitz University of Ulm
Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Carsten Denkert
Carsten Denkert Philipp University of Marburg
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Jens Huober
Jens Huober Kantonsspital St. Gallen
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Volkmar Müller
Volkmar Müller Universität Hamburg
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Tanja Fehm
Tanja Fehm Heinrich Heine University Düsseldorf

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in medicine or healthcare but are looking for flexible learning options, online degrees can provide valuable career openings. With healthcare evolving rapidly, many students now pursue specialized programs and leadership roles through accredited online options.

For those interested in mental health, psych np online programs offer a pathway to becoming a psychiatric nurse practitioner. These programs deliver focused training that can lead to rewarding careers in behavioral health.

Many graduates also consider administrative roles in healthcare. Options like the cheapest mha programs online and affordable mha online degrees can prepare students for management and leadership positions, often at a lower cost and with increased flexibility.

Nurses aiming for the highest clinical practice level may explore the best online bsn to dnp programs. These advanced degrees support a significant step up in expertise, opening doors to more autonomous clinical roles.

Best Scientists Citing Sibylle Loibl

Trending Scientists

Recently Published Articles